Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, controlled with active treatment (tramadol 100 mg) and placebo, parallel groups, Phase II clinical trial to establish the effective dose between 4 strengths of E-58425 for moderate to severe dental pain [Ensayo clínico de fase II aleatorizado, doble ciego, controlado con tratamiento activo (tramadol 100 mg) y placebo, de grupos paralelos, para establecer la dosis eficaz de entre 4 concentraciones de E-58425 para dolor dental de moderado a intenso]

Next Previous
X
Search
Trial Profile

A randomized, double-blind, controlled with active treatment (tramadol 100 mg) and placebo, parallel groups, Phase II clinical trial to establish the effective dose between 4 strengths of E-58425 for moderate to severe dental pain [Ensayo clínico de fase II aleatorizado, doble ciego, controlado con tratamiento activo (tramadol 100 mg) y placebo, de grupos paralelos, para establecer la dosis eficaz de entre 4 concentraciones de E-58425 para dolor dental de moderado a intenso]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib/tramadol (Primary) ; Tramadol
  • Indications Dental pain; Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Laboratorios Dr. Esteve

    • Most Recent Events

    • 30 Sep 2016 Results (n=334) assessing efficacy and safety presented at the 16th World Congress on Pai.
    • 16 Oct 2013 Primary endpoint 'Sum-of-pain-intensity-difference' has been met. as reported by an Esteve media release.
    • 15 Oct 2013 Top-line results published in an Esteve media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top